ClinicaliQ Trial Snapshot
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) — Recruiting • Phase II • Rheumatology • NCT02991469.
- SKYPS Trial Summary.
- Sarilumab dose-finding study in children with systemic juvenile idiopathic arthritis to establish safe, effective dosing and assess safety outcomes.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA. Conditions: Juvenile Idiopathic Arthritis Interventions: Sarilumab SAR153191 (REGN88) Lead Sponsor: Sanofi Planned Enrollment: 51 participants